The in vitro viral lymphoproliferative response of pigs vaccinated against foot-and-mouth disease virus (FMDV) has been characterized. Peripheral blood mononuclear cells from immunized animals up to 1 year post-immunization (p.i.) showed a time-dependent FMDV-specific response, as assayed by virusspecific cellular blastogenesis. The optimum viral concentration decreased with time (around 20 weeks p.i.), and the response was faster and weaker. Lymphoproliferation appeared to be mainly due to CD4 + T cells. The response was heterotypic, being induced by all FMDV serotypes tested (C, A and O) after only two vaccinations with FMDV of serotype C (C-$8). Each individual structural protein assessed (VP1, VP2 and VP3) induced proliferation, with VP3 and VP1 being more effective stimulators. In vitro serum neutralization activity and FMDV-specific IgG production were found to be active even at 1 year p.i.
Introduction
Foot-and-mouth disease is a highly contagious disease of cloven-hoofed animals, mostly cattle and swine. The causative agent of the disease is the only aphthovirus of the Picornaviridae family, namely foot-and-mouth disease virus (FMDV). The infectious particle is composed of a single-stranded positive-sense RNA molecule of about 8500 nucleotides (Bachrach, 1977) , folded in an icosahedral capsid made of 60 copies each of four proteins, VP1, VP2, VP3 and VP4 (Rueckert, 1990) . Although only VP1 has been shown to induce neutralizing antibodies in isolation (Bachrach et al., 1975; Laporte et al., 1973) , VP2 and VP3 also contribute to the antigenicity of the intact virus particle (Barnett et al., 1989; Baxtet al., 1989; Kitson et al., 1990; S/tiz et al., 1991) .
In many enzootic areas the disease is controlled by using chemically inactivated whole-virus vaccines (Barteling & Vreeswijk, 1991) . Several factors impair efficient vaccination of animals against FMDV infection, among them the extensive antigenic diversity of this virus (reviewed in Domingo et al., 1990 ) and the association of field outbreaks with vaccine strains (King et al., 1981; Beck & Strohmaier, 1987; CarriUo et al., 1989) . Consequently, considerable effort is being focused on the development of new, safer and broadly protective vaccines (for review, see Brown, 1989) . Immunization with VP1 and fragments of this protein, including synthetic peptides, elicited neutralizing antibodies and resulted in natural hosts becoming protected against virus challenge (Laporte et al., 1973; Bachrach et al., 1975; Kleid et al., 1981 ; Bittle et al., 1982; Strohmaier et al., 1982; Francis et al., 1985; DiMarchi et al., 1986; Broekhuijsen et al., 1987) ; however, the immunity induced was poor. The immunogenicity of synthetic peptides modelled after the main antigenic sites of VP1 was increased when fused with hepatitis B virus core protein (Clarke et al., 1987) .
Genetic restriction of the response to synthetic peptides by the major histocompatibility complex (MHC) has been described in mice . In this animal model, an FMDV-specific antibody response has been shown to be T cell-dependent (Collen et al., 1989) . In cattle, FMDV T cell epitopes are serotypicaUy cross-reactive (Collen & Doel, 1990) and the inclusion of a T cell immunodominant site, located at VP1 positions 21 to 40 of FMDV O1 Kaufbeuren (O1Kb), has been shown to overcome the genetic restrictions of cattle and enabled recognition of a synthetic FMDV peptide . Thus, inclusion of appropriate FMDV-specific T cell determinants in the design of new vaccines based on synthetic peptides should improve their immunogenicity. Meanwhile, it is still necessary to locate new T cell epitopes within FMDV proteins and to study how MHC restriction affects the recognition of these epitopes by each of the relevant natural hosts of the virus.
As a first step in the characterization of FMDV T cell epitopes in swine, we have analysed the in vitro FMDVspecific lymphoproliferative response in vaccinated 0001-0958 © 1992 SGM pigs. In this report we show that peripheral blood mononuclear cells (PBMC) from these animals responded to virus strains of different serotypes, as well as to purified structural proteins. A lymphoproliferative response, as well as significant titres of in vitro neutralizing FMDV-specific immunoglobulins, was found even up to I year post-immunization (p.i.).
Methods
Viruses and cells. FMDV strains of serotypes C, A and O, i.e. C1 Santa Pau Sp70 (C-$8), C10berbayern (CIObb), A5 Westerwald (A5Ww) and O1Kb were used. Virus was grown on monolayers of BHK-21 cells and purified on a CsC1 gradient as previously described (Sfiiz et al., 1989) . A purified C-$8 preparation was quantified by its A260_305 (Sfiiz et al., 1989) and used as a standard for viral mass estimation. Virus stocks were quantified by an enzyme-linked immunodot assay using either monoclonal antibody (MAb) SD6 that recognizes a continuous epitope on VP1 of C-$8 and CIObb (Mateu et al., 1987) , or MAb 23JH4 which binds all FMDV strains, except those of scrotype SAT-2 (Sfiiz et al., 1989) . African swine fever virus (ASFV) or BHK-21 cellular extracts were used as controls. IBRS-2 cells were used to obtain viral antigen for ELISAs.
Vaccine preparation and immunization of animals. Purified C-$8 virus stocks were chemically inactivated according to the method of Bahnemann (1974) . Complete inactivation was confirmed by p.f.u. titration. Antigenicity was monitored by immunization of BALB/c mice with 5 ttg of inactivated virus (corresponding to about 1 x l0 T p.f.u), followed by titration of the neutralizing activity present in the sera of the animals as described by Stave et al. (1986) . No virus was recovered from immunized mice.
Three 5-month-old, SLA inbred miniature pigs (Sachs et aL, 1976) , of the SLA d/d (dd) haplotype (861, 863 and 864), were immunized intradermaUy with 5 x 107 p.f.u. (5 to 15 ilg) of chemically inactivated C-$8 FMDV in Freund's complete adjuvant. The animals were boosted 4 weeks later by a second equivalent dose in Freund's incomplete adjuvant. Animal 865 was immunized by the same regime using PBS instead of virus. Unfortunately, animal 864 died 3 weeks after the first immunization from causes other than FMDV.
Purification of proteins. FMDV structural proteins were separated by 11% (w/v) urea discontinuous PAGE (Laemmli, 1970) . The proteins were electrophoretically transferred onto nitrocellulose sheets (Schleicher & Schueii), followed by solubilization of individual proteins in DMSO, as described by Abou-Zeid et al. (1987) . Individual proteins were identified by Western blot analysis (Sfiiz et al., 1989 ) using protein-specific rabbit polyclonal sera (Strebel et al., 1986) .
Proliferation assays. Blood from immunized swine was collected into 5 mM-EDTA pH 7.2, and used immediately for isolation of PBMC. Briefly, after erythrocyte sedimentation in 0-72% dextran, PBMC were isolated from the leukocyte-enriched plasma by centrifugation on a Percoll (Pharmacia) discontinuous gradient as previously described (Gonz~lez et al., 1990) . After three washes with 0.1% glucose in PBS, PBMC were counted and resuspended in RPMI 1640 medium supplemented with 10% heat-inactivated foetal calf serum, 2 mMglutamine, 1 mM-sodium pyruvate, 20 mM-HEPES, 50 ~tM-2-mercaptoethanol, 100 units/m] penicillin, 100 p.g]ml streptomycin and various concentrations of purified FMDV or nitrocellulose-bound viral polypeptides. To control the specificity of the assay, ASFV BHK-21 cellular extracts or non-specific nitrocellulose-bound proteins were included. Concanavalin A (Flow Laboratories), at 2-5 ktg/well, was also included as a control. Proliferation assays were carried out as described by Collen & Doel (1990) , except that 200 ~tl of a suspension of 2 x 106 cells/ml was used per well, and incorporation of radioactivity into cellular DNA was measured after 6 h incubation with 1 ~tCi of [3Hlthymidine per well. Results are expressed as Ac.p.m. (c.p.m. sample --c.p.m, medium alone). The response was considered positive only when the mean Ac.p.m. for a sample was at least three times the standard error (S.l~.) obtained in the absence of antigen (background), and the response was dose-dependent. With few exceptions, the s.
•. within assays was lower than 30% of the mean Ac.p.m. for values higher than the background level (< 1000 c.p.m.).
For blocking of specific proliferation, the following marine IgG2 anti-swine hybridomas were used: 74-12-4, anti-CD4; 76-2-11, anti-CD8; 74-11-10, anti-SLA class I (Pescovitz et al., 1984) ; MSA3, anti-SLA class I1 (Hammerberg & Schurig, 1986) . Ten ttg of the appropriate purified MAb was added per well, at the beginning of culture, and plates were processed as above. The addition of each of the MAbs to concanavalin A-stimulated PBMC resulted in inhibitions that never exceeded 2% of the proliferation obtained with the untreated control, even at concentrations twofold higher than those used in the inhibition assay. An irrelevant IgG2 MAb, elicited against infectious pancreatic necrosis virus (Babin et al., 1991) , was used as a control.
Serum neutralization assays. Serum neutralization tests were carried out by plaque reduction assay (Stave et al., 1986) . The titres were determined as the 70% plaque reduction neutralization (PRN-70) value by the iogit-log transformation method (Trautman & Harris, 1977) .
ELISA. An EL1SA was developed to measure swine FMDV-specific IgG 1 and IgG2 present in sera from immunized animals. The assay was carried out using biotin-labelled routine MAbs, anti-swine IgG 1 and IgG2 (kindly provided by Dr C. R. Stokes), at 2 ~tg/ml, as described by Mulcahy et al. (1990) with some modifications. Briefly, ascitic fluid from SD6 hybridoma was coated onto the plates, and supernatant of IBRS-2 cells infected with FMDV C-$8 was used as antigen. Serum from a non-immunized pig was used as a background control. In this assay, an A62o of 0-7 always fell on the linear part of the curve and, therefore, titres were expressed as the log of the reciprocal of the serum dilutions that gave an A62o of 0.7. The mean background absorbance in the assay was 0.2.
Results

Establishment of an in vitro lymphoproliferative assay for pigs immunized with FMDV
The optimum conditions for virus-specific proliferation of cells from pigs at 6 weeks p.i. were investigated; best results were obtained with a cell density of 2 x 106 cells/ml (data not shown) and a 5 day incubation (Fig. 1) . After 20 weeks, the optimum proliferative response was achieved at day 4 post-stimulation, although it was only slightly higher than that at day 5 (see an example at week 46 in Fig. 1 ). Maximum stimulation was reached with a final concentration of 200 Ixg/ml of purified virus during the first weeks, dropping to 40 ktg/ml after 20 weeks p.i. (see examples at weeks 2 and 21 in Fig. 2 ). Although the magnitude of the response varied greatly between weeks, it was consistent within assays and tended to wane after week 32 p.i. (see below). The response was antigen dosedependent and higher antigen concentrations than that found to be optimal were inhibitory (Fig. 2) . Neither ASFV nor an extract from uninfected BHK-21 cells induced a proliferative response of PBMC from any of the animals (data not shown).
To determine the phenotype of the cells responsible for the in vitro proliferative response, MAbs against porcine CD4, CD8, SLA class I and SLA class II antigens were used as described in Methods. Except for anti-CD8 antibody, the MAbs tested inhibited by more than 70% the C-$8 FMDV-specific proliferation of PBMC from vaccinated animals ( Table 1 ). The results suggest that the lymphoproliferative response was mainly due to a CD4 ÷ subset of T lymphocytes.
Specificity of the lymphoproliferative response
FMDV strains other than that included in the vaccine preparation (C-$8) were used to analyse the crossreactivity of the proliferative response of PBMC from immunized animals. The strongest response was induced by C1Obb and C-$8 viruses, followed by A5Ww, with the O1Kb strain causing the lowest response (Fig. 3) . Similar results were obtained at different weeks p.i., although the magnitude of the response also varied from week to week (data not shown).
To determine the contribution of different structural polypeptides to the in vitro proliferative response of cells from the immunized animals, C-$8 FMDV VP1 to VP3 capsid proteins were purified, transferred onto nitrocellulose membranes and identified as described in Methods. When these polypeptides were assessed for their capacity to induce a lymphoproliferative response of PBMC from vaccinated animals, a dose-dependent response was found for each of them (Fig. 4) . Although lower than for the whole virus, the response was always higher for VP3 and VPI than for VP2. The magnitude of these responses also fluctuated between weeks (data not shown), in the same way as those obtained with the whole virus.
Time course study of the immune response
This study was carried out with two pigs immunized with C-$8 FMDV (861 and 863) and one pig immunized with PBS (865). The in vitro proliferative response of PBMC was followed over a 25 week period for animals 861 and 865, (O) titres, as well as the in vitro neutralization titres (n) were determined as described in Methods. Specific lgG titres are expressed as the log of the reciprocal of the dilution that gave an A620 of 0.7 (0-5 over the background level). In vitro neutralization titres are expressed as PRN-70. The titres of PBS-inoculated animal 865 were lower than 0.3 throughout the period of the study. Arrows indicate the times at which animals were inoculated.
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and over 50 weeks for animal 863. The results showed a profile that displayed peaks of high and low response (Fig. 5) , the values being higher for pig 863. The specific response of PBMC to purified FMDV antigens from animal 865 never exceeded three times the s.E. obtained in the absence of viral antigen.
Additional time course studies were carried out to monitor the serum neutralization activity and the isotype of the immunoglobulins produced. Serum neutralization titres, expressed as PRN-70, remained higher than 3-00 from the fifth week p.i. (Fig. 6) . In contrast to the results of the proliferative response, the PRN-70 of both immunized animals displayed slight fluctuations between weeks, but the titres for animal 863 were always higher than those of pig 861.
Specific antioFMDV IgG1 and IgG2 titres (Fig. 6 ) of immunized animals gave profiles that were always higher than that of the control animal 865 (background level). In the case of pig 863, significant IgG1 and IgG2 titres were found as late as 40 and 50 weeks p.i., respectively.
Discussion
In the present report we have analysed, for the first time in swine, the in vitro specific proliferative response of PBMC from pigs immunized with FMDV to whole virus and purified viral structural proteins. The magnitude of the polyclonal proliferative responses is known to fluctuate to an extent within and between experiments; however, several consistent observations can be drawn from our results. The response was antigen dosedependent and reached a maximum at day 5 poststimulation. The optimum virus concentration decreased after several weeks p.i., resulting in a quicker, but lower, proliferative response. The range of optimal concentrations (40 to 200 ~tg/ml) was higher than that found in cattle, 1 to 5 Ixg/ml (Wardley et al., 1979; Collen & Doel, 1990; . This variation could be due to the different procedures used for quantification of virus, which allowed either detection of the whole virus and subunits by antigenic reactivity (in our case) or estimation of the mass of intact virus. However, other factors could influence the outcome of the lymphoproliferative response, i.e. virus strain, assay conditions, and variations in antigenic sensitivity between lymphocytes from different individuals and/or species. The FMDV specificity was confirmed after ASFV and BHK-21 cellular extracts failed to induce a proliferative response.
A contribution of CD4 ÷ lymphocytes to the proliferative response to FMDV in swine is indicated by the inhibition (over 70~o) achieved with anti-CD4 and anti-SLA class II MAbs, together with the positive response obtained with purified structural proteins. The basis of the inhibition obtained with anti-SLA class I MAb is somewhat unclear at present, but it may be independent of antigen presentation since an anti-CD8 MAb did not inhibit to the same extent. Long term virus-specific T cell clones derived from PBMC lines of pig 863 have been selected. Further characterization of these clones will help to clarify the nature of the cell population(s) involved in this response.
It is clear that the incorporation of specific T cell epitopes in new synthetic vaccines would be of great interest (reviewed in Brown, 1989) . Due to the high antigenic variability that FMDV exhibits (reviewed in Domingo et al., 1990) , these epitopes should be as broadly cross-reactive as possible. Our results indicate that the lymphoproliferative response induced in vaccinated pigs is heterotypic. The highest response was obtained for homotypic virus (serotype C), followed by serotypes A and O. FMDV C1Obb induced a better response than the vaccine strain (C-$8); a similar observation was described in cattle by Collen & Doel (1990) with heterotypic viruses. This could be explained either by a better presentation of the same T cell epitope in the heterologous virus or by the presence on the C1Obb strain of nearby residues that enhance the efficiency of such an epitope as a lymphoproliferation inducer. A possible role of neighbouring amino acid residues in the efficient presentation of a T cell determinant has been described by Boyer et al. (1990) .
A significant proliferative response of PBMC from vaccinated pigs was also induced by purified FMDV capsid proteins, with the highest stimulations being obtained for VP3 and VP1. Similar results have been obtained recently using recombinant C-$8 FMDV capsid proteins expressed in Escherichia coli (A. Rodriguez et al., unpublished results). Serotype-specific T cell epitopes, recognized by vaccinated cattle, have recently been located mainly in VP1, whereas serotype cross-reactive clones have been described as recognizing VP3 epitopes (Collen & Doel, 1991) . A serotype crossreactive T cell epitope, recognized by cattle, has been identified at VP3 residues 97 to 110 of the O1Kb strain (T. Collen & T. Doel, personal communication) . Interestingly, this region is highly conserved among FMDV of serotypes A, C and O. Our preliminary results suggest the presence of a swine T cell epitope in, or near, this region in C-$8 (A. Rodriguez, unpublished results). Thus, it will be very interesting to confirm whether this VP3 epitope is not only serotype cross-reactive but also broadly recognized by different species; if so, it would be a clear candidate for incorporation into a new synthetic vaccine.
Results from the time course study suggest that memory lymphocytes are circulating in the blood up to 1 year p.i. The significance of the alternating periods of high and low response, which were also described for cattle , is unclear at present, and further experiments to clarify this point are in progress.
In vitro FMDV serum neutralization titres (PRN-70) of vaccinated animals remained higher than 3.00 from the first few weeks up to 1 year p.i., decreasing slowly throughout the study period. Likewise, high levels of FMDV-specific IgG 1 and IgG2 were detected; the IgG 1 response was apparently shorter lasting than that of IgG2. No relationship could be established between the proliferation profile and IgG titres, however, it is interesting that the most responsive animal (863) also had the higher serum neutralization titres.
Evidence available for vaccinated cattle indicates a relevant role for IgG1 versus IgG2 in this animal model (Mulcahy et al., 1990; Collen & Doel, 1991) . Unfortunately, we could not challenge our animals to assess this point. However, a variety of factors can influence the generation of specific antibodies of different Ig subclasses during the immune response, and very little is known about their functional activity in swine.
At present, studies are being carried out to locate precisely T cell epitopes on VP1 and VP3. Putative VP3 cross-reactive epitopes recognized by different host animals will be the focus of these studies, as candidates for incorporation into new synthetic foot-and-mouth disease vaccines.
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